Molecular neurobiologyJul 17, 2026

Sirtuin Signaling in Parkinson's Disease and Brain Cell Loss: Molecular Understanding and Possible Treatments

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 18, 2026

Abstract

Mitochondrial dysfunction and metabolic dysregulation are central contributors to Parkinson's disease (PD).

Neurodegenerative diseases involve progressive neuronal loss due to protein aggregation and other factors.
Parkinson's disease is characterized by the degeneration of dopamine-producing neurons and the accumulation of alpha-synuclein aggregates.
Sirtuins, a family of NAD+-dependent deacetylases, play significant roles in neuronal survival and metabolic balance.
SIRT1 is involved in regulating alpha-synuclein aggregation, autophagy, and inflammatory responses.
SIRT3 helps maintain mitochondrial health and lower oxidative stress.
Inhibition of SIRT2 has shown protective effects against neurotoxicity in experimental models.

Simplified

Neurodegenerative diseases are characterized by progressive neuronal loss driven by protein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. Among these, Parkinson's disease (PD) is a prevalent disorder marked by degeneration of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein aggregates. Emerging evidence indicates that mitochondrial dysfunction and metabolic dysregulation are central contributors to PD pathogenesis. Sirtuins (SIRT1-SIRT7), a family of nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases, have emerged as key regulators of neuronal survival and metabolic homeostasis. Mechanistically, SIRT1 regulates α-synuclein aggregation, autophagy, and neuroinflammatory signaling, while SIRT3 preserves mitochondrial integrity and reduces oxidative stress. In contrast, SIRT2 has been implicated in microtubule destabilization and neurotoxicity, and its inhibition has demonstrated neuroprotective effects in experimental models. This review provides a comprehensive, up-to-date synthesis of the molecular mechanisms underlying sirtuin-mediated neuroprotection in PD and related neurodegenerative disorders. We further discuss the translational potential of targeting sirtuin pathways, including pharmacological modulators and NAD+-boosting strategies, while addressing current limitations and future directions for clinical translation.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 4

authors report competing interests

4 report none

PubMed

Sirtuin Signaling in Parkinson's Disease and Brain Cell Loss: Molecular Understanding and Possible Treatments

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief